Ankyrin Repeat Binding Protein for Blocking TSLP Receptor Complex

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments lack a novel binding protein or domain, such as ankyrin repeat proteins, that can specifically target TSLP to inhibit the formation of the TSLP-TSLPR/IL-7Rα complex, thereby controlling allergic and inflammatory responses.

Innovation Solution

A recombinant binding protein comprising ankyrin repeat domains, specifically designed to bind to TSLP, blocking the formation of the TSLP-TSLPR/IL-7Rα complex and inhibiting pro-inflammatory signaling.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If antibodies are used to target TSLP, then TSLP binding and inhibition of TSLP-TSLPR/IL-7Rα complex formation is achieved, but the lack of novel binding protein types limits therapeutic options and drug development diversity

Engineering Contradiction:

Improvediversity of binding protein typesVSAvoidspecificity and affinity for TSLP

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent changes the fundamental parameter of protein type from antibodies to ankyrin repeat proteins, creating a novel class of TSLP-binding proteins while maintaining high specificity and affinity through optimized repeat domain structures

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The invention creates composite therapeutic options by combining different binding protein types (antibodies and ankyrin repeat proteins) with distinct structural and functional characteristics, expanding the toolkit for TSLP targeting

Inventive Principle:

Principle #40Composite materials

2Object-affected harmful factors

If TSLP-TSLPR/IL-7Rα complex formation is allowed to proceed, then normal immune signaling is maintained, but pro-inflammatory responses and allergic diseases are promoted

Engineering Contradiction:

Improvepro-inflammatory signalingVSAvoidreceptor signaling function

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The ankyrin repeat protein binds to TSLP in advance, preventing the formation of the TSLP-TSLPR/IL-7Rα complex before it can activate pro-inflammatory signaling pathways, thereby blocking the harmful effect at its source

Inventive Principle:

Principle #9Preliminary anti-action

Solution Approach 2:

The ankyrin repeat protein acts as an intermediary molecule that binds to TSLP and prevents its interaction with the TSLPR/IL-7Rα receptor complex, mediating the blocking effect without directly interacting with the receptor

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The recombinant binding protein effectively blocks the interaction between TSLP and its receptor, reducing pro-inflammatory signaling and controlling TSLP-related diseases like allergic diseases.

Implementation Method 1

Multiple binding motifs in tandem form a large domain and thus mediate protein-protein interactions

Methodology Applied

Scientific EffectProtein-protein interaction:

Data Source

PatentUS20250376501A1Recombinant binding protein targeting TSLP and use thereof

Publication Date: 2025.12.11 JINGYUAN BIOSCIENCES (SUZHOU) CO LTD

AI summary

Disclosed are a recombinant binding protein targeting TSLP and the use thereof. The recombinant binding protein comprises at least one ankyrin repeat domain that specifically binds to TSLP, wherein the ankyrin repeat domain comprises three tandem binding domains, and each binding domain comprises four binding active regions. The recombinant binding protein of the present invention has excellent binding activity to TSLP, and effectively blocks the interaction between TSLP and a receptor thereof, thereby effectively controlling TSLP-related diseases.